Core Viewpoint - Hendi Pharmaceutical (301211) announced that three shareholders plan to collectively reduce their holdings by up to 2.33% of the company's shares due to personal financial planning [1][2]. Shareholder Reduction Details - Shareholder Ningkang Enterprise Management Center (Limited Partnership) holds 23,490,000 shares (5.63% of total shares) and plans to reduce up to 4,176,000 shares (1%) within three months after the announcement [1]. - Shareholder Beikang Enterprise Management Center (Limited Partnership) holds 7,830,000 shares (1.88% of total shares) and plans to reduce up to 1,392,000 shares (0.33%) within three months after the announcement [1]. - Shareholder Lei Xiaoyan holds 15,660,000 shares (3.75% of total shares) and plans to reduce up to 4,176,000 shares (1%) within three months after the announcement [1]. Market Performance - Hendi Pharmaceutical's stock price approached its yearly high, reaching 16.95 yuan per share on November 10, close to the year's peak of 16.97 yuan [2]. - On November 12, the stock price fell by 2.39%, closing at 15.50 yuan per share, with a total market capitalization of 6.473 billion yuan [2]. Financial Performance - The three shareholders' total potential cash-out from the share reduction could be up to 151 million yuan based on the latest stock price [3]. - For the first three quarters, the company reported revenue of 319 million yuan, a year-on-year decrease of 4.52%, and a net profit attributable to shareholders of 20.93 million yuan, down 71.96% [3]. - The third quarter alone saw revenue of 84.13 million yuan, a decline of 8.68%, and a net profit of 2.39 million yuan, down 61.3% [3]. - The company has experienced continuous negative growth in revenue and net profit since the first quarter of the previous year, primarily due to a decrease in the sales volume of ibuprofen [3].

Core Viewpoint - Hendi Pharmaceutical's subsidiary, Wuhan Baike Pharmaceutical Development Co., Ltd., successfully passed an FDA inspection, confirming compliance with quality standards and enhancing its competitiveness in the international market [1] Group 1: FDA Inspection - The FDA inspection took place from March 10 to March 14, 2025, focusing on raw materials such as fludarabine phosphate, milrinone, granisetron, and furosemide [1] - The inspection report from the FDA confirmed the completion of the inspection, indicating that Baike Pharmaceutical met the necessary requirements [1] Group 2: Market Implications - The successful inspection demonstrates the company's commitment to maintaining quality systems that align with FDA standards, which is crucial for expanding into international markets [1] - This achievement is expected to enhance the competitiveness of the company's raw material products in the global market [1]